VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day VRTX SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:02 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-0.9%
8/4/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-20.6%
5/5/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-10.0%
2/10/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
-3.1%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX
SPY
QQQ
SPX
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
VRTX SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/24
01:50 pm
vrtx
Neutral
Why a 63% Vertex Selloff Didn't Scare Off a New $13 Million Investor [Yahoo! Finance]
12/22
09:33 pm
vrtx
Low
Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress [Yahoo! Finance]
12/22
04:00 pm
vrtx
Low
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
12/16
12:00 pm
vrtx
Low
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
12/14
03:09 am
vrtx
Low
How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance]
12/13
12:51 pm
vrtx
Low
Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? [Yahoo! Finance]
12/11
02:30 pm
vrtx
Low
Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance]
12/10
03:23 pm
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.
12/9
08:11 am
vrtx
Low
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
11/3/2025
04:02 pm
vrtx
-0.9%
BEAT
8/4/2025
04:01 pm
vrtx
-20.6%
BEAT
5/5/2025
04:01 pm
vrtx
-10.0%
BEAT
2/10/2025
04:01 pm
vrtx
-3.1%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/10
03:07 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/10
03:07 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/9
08:11 am
Upgrades
Strong-Buy
UBS Group AG
Low
-1.1%
12/5
10:30 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-0.8%
12/5
10:30 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-0.8%
12/3
10:33 am
Upgrades
Equal-Weight
Overweight
Morgan Stanley
Low
2.2%
12/3
10:33 am
Upgrades
Equal-Weight
Overweight
Morgan Stanley
Low
2.2%
12/3
08:44 am
Upgrades
Equal Weight
Overweight
Morgan Stanley
Medium
5.5%
12/3
08:44 am
Upgrades
Equal Weight
Overweight
Morgan Stanley
Medium
5.5%
12/5
04:17 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: WAGNER CHARLES F JR
12/5
04:13 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Tatsis Ourania
12/5
04:11 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: LEIDEN JEFFREY M
12/5
04:06 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Biller Jonathan
12/3
04:34 pm
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: LEIDEN JEFFREY M
12/3
01:02 pm
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
12/3
11:25 am
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
12/3
11:00 am
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: Tatsis Ourania
12/3
10:53 am
vrtx
Low
Form 144 VERTEX PHARMACEUTICALS Filed by: Biller Jonathan
Show more
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%